Evidence map›Paper›PMID 28205047›Full record

ArticleCancer causes & control : CCC2017

Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium.

Jennifer Ose, Helena Schock, Elizabeth M Poole, Matti Lehtinen, Kala Visvanathan, Kathy Helzlsouer, Julie E Buring, I-Min Lee, Anne Tjønneland, Marie-Christine Boutron-Ruault and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Prospective Analysis of Circulating Biomarkers and Ovarian Cancer Risk in the UK Biobank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 12 countries.

Jennifer OseDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Baden-Württemberg, Germany.
Helena SchockDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Baden-Württemberg, Germany.
Elizabeth M PooleChanning Division of Network Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Matti LehtinenDepartment of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
Kala VisvanathanDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Kathy HelzlsouerDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Julie E BuringDivision of Preventive Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
I-Min LeeDivision of Preventive Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Anne TjønnelandUnit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
Marie-Christine Boutron-RuaultUniversité Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Amalia MattielloDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
N Charlotte Onland-MoretDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
María-José SánchezEscuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Annika IdahlDepartment of Clinical Sciences, Obstetrics and Gynecology, Umea University, Umea, Sweden.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Sabina RinaldiSection of Nutrition and Metabolism, International Agency for Research on Cancer (IARC), Lyon, France.
Melissa A MerrittDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shelley S TworogerChanning Division of Network Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Baden-Württemberg, Germany.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Baden-Württemberg, Germany. r.fortner@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0002-1426-8505
Brigham and Women's Hospital · USGerman Cancer Research Center · DEJohns Hopkins University · USKarolinska Institutet · SECentre international de recherche sur le cancer · FRDanish Cancer Society · DKFederico II University Hospital · ITHellenic Health Foundation · GRImperial College London · GBNational Institutes of Health · USUmeå University · SEUniversidad de Granada · ESUniversité Paris-Sud · FRUniversity Medical Center Utrecht · NLUniversity of Oxford · GB

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESISU01CA086308 · NCI · JOHNS HOPKINS UNIVERSITY · PI HELZLSOUER, KATHY J · 2000 to 2004
$4.2M
The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upUM1CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2014 to 2018
$4.0M
Hormone levels during pregnancy and maternal ovarian cancerR01CA120061 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LUKANOVA, ANNEKATRIN · 2006 to 2010
$2.0M
TRIAL OF VITAMIN E, BETA-CAROTENE &ASPRIN IN WOMENR01HL043851 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1991 to 2000
$1.6M
The Women's Health Study: Addition of New Data to Maximize its Research ImpactRC1HL099355 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2009 to 2010
$992k
Cancer Research UK 14136Cancer Research UK 16491Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA120061NCI NIH HHS U01 CA086308NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA182913NCI NIH HHS UM1 CA186107NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS RC1 HL099355World Health Organization 001
6 · The paper itself

Abstract

purposeBiologic evidence suggests that the Insulin-like growth factor (IGF)-family may be involved in the etiology of epithelial invasive ovarian cancer (EOC). However, prospective studies investigating the role of IGF-I in ovarian carcinogenesis have yielded conflicting results.

methodsWe pooled and harmonized data from 6 case-control studies nested within the Ovarian Cancer Cohort Consortium to investigate the association between pre-diagnosis IGF-I concentrations and subsequent risk of EOC. We evaluated IGF-I concentrations and risk of EOC overall and by tumor subtype (defined by histology, grade, stage) in 1,270 cases and 2,907 matched controls. Multivariable conditional logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI).

resultsDoubling of IGF-I concentration was associated with significantly lower risk of overall EOC [OR

conclusionsThese results suggest that IGF-I concentrations are inversely associated with EOC risk, independent of histological phenotype. Future prospective research should consider potential mechanisms for this association, including, considering other members of the IGF-family to better characterize the role of IGF-signaling in the etiology of EOC.

Indexed as

AdultAgedCase-Control StudiesFemaleHumansInsulin-Like Growth Factor IMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsProspective StudiesRisk FactorsInsulin-Like Growth Factor IDevelopmental pathwaysEpithelial ovarian cancerHistological subtypesIGF-I

Identifiers

PMID28205047
PMCPMC5447004
OpenAlexW2587867268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.